Ketazocine
From Wikipedia, the free encyclopedia
Jump to: navigation, search
Systematic (IUPAC) name | |
---|---|
(2S,6R,11R)-3-(cyclopropylmethyl)-8-hydroxy-6,11-dimethyl-3,4,5,6-tetrahydro-2,6-methano-3-benzazocin-1(2H)-one
|
|
Clinical data | |
Routes of administration |
Oral |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | 36292-69-0 Y |
ATC code | none |
PubChem | CID 3054741 |
ChemSpider | 2316328 Y |
UNII | 6IO4IG518S Y |
KEGG | D04649 Y |
Chemical data | |
Formula | C18H23NO2 |
Molar mass | 285.38 g/mol |
3D model (Jmol) | Interactive image |
|
|
|
|
(verify) |
Ketazocine (INN), also known as ketocyclazocine, is a benzomorphan derivative used in opioid receptor research. Ketocyclazocine is an exogenous opioid that binds to the κ opioid receptor.[1]
Activation of this receptor is known to cause sleepiness, a decrease in pain sensation and (potentially) dysphoria, paranoia, and hallucinations. It also causes an increase in urine production because it inhibits the release of vasopressin. (Vasopressin is an endogenous substance that assists in regulating fluid and electrolyte balance in the body and decreases the amount of water released into the urine.)
Unlike other opioids, substances that only bind to the κ receptor theoretically do not depress the respiratory system.
See also[edit]
References[edit]
- ^ Leander JD (Sep 1982). "Effects of ketazocine, ethylketazocine and phenazocine on schedule-controlled behavior: antagonism by naloxone". Neuropharmacology. 21 (9): 923–8. doi:10.1016/0028-3908(82)90085-5. PMID 6128693.
MOR |
|
---|---|
DOR |
|
KOR |
|
NOP |
|
Unsorted | |
Others |
|
See also: Peptide receptor modulators
|